Milsaperidone

N/A

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameMilsaperidone
Drug Alias NameBysantiVHX-896P-88
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderSchizophreniaDepressive Disorder, Major +[4] 
Global Approved IndicationsBipolar I DisorderSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/02/20
Country/TerritoryCzechiaBulgariaUnited States +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVanda Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVanda Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsBipolar I DisorderSchizophreniaDepressive Disorder, Major +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A